Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease

Background Glucocerebrosidase gene mutations are a common genetic risk factor for Parkinson's disease. They exhibit incomplete penetrance. The objective of the present study was to measure microglial activation and dopamine integrity in glucocerebrosidase gene mutation carriers without Parkinson's disease compared to controls. Methods We performed PET scans on 9 glucocerebrosidase gene mutation carriers without Parkinson's disease and 29 age-matched controls. We measured microglial activation as C-11-(R)-PK11195 binding potentials, and dopamine terminal integrity with F-18-dopa influx constants. Results The C-11-(R)-PK11195 binding potential was increased in the substantia nigra of glucocerebrosidase gene carriers compared with controls (Student t test; right, t = -4.45, P = 0.0001). Statistical parametric mapping also localized significantly increased C-11-(R)-PK11195 binding potential in the occipital and temporal lobes, cerebellum, hippocampus, and mesencephalon. The degree of hyposmia correlated with nigral C-11-(R)-PK11195 regional binding potentials (Spearman's rank, P = 0.0066). Mean striatal F-18-dopa uptake was similar to healthy controls. Conclusions In vivo C-11-(R)-PK11195 PET imaging detects neuroinflammation in brain regions susceptible to Lewy pathology in glucocerebrosidase gene mutation carriers without Parkinson's. (c) 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Automated summary

The study found that carriers of glucocerebrosidase gene mutations without Parkinson's disease also present neuroinflammation. Microglial activation was observed in brain regions susceptible to Lewy pathology. Importantly, the degree of hyposmia was positively correlated with nigral binding potential.